1 Oncologic Drugs Advisory Committee on MTP for Osteosarcoma IDM Pharma, Inc. May 9, 2007 Silver Spring, MD IDM Pharma, Inc. May 9, 2007 Silver Spring,

Slides:

Advertisements

Similar presentations

Vilnius, 29 June 2007 CIOMS Recommendations on Ethics in Medical Research The Eighth Global Forum on Bioethics in Research Gottfried Kreutz Dr. med., Dipl.-Chem.;

Advertisements

Medical Image Database Resource for Software Tools Evaluation and MIRC Laurence P Clarke, PhD Barbara Croft PhD Carl Jaffe MD Gary Becker MD Dan Sullivan.

Statistical Considerations for Implementing the FDA CV Guidance for T2DM Craig Wilson, PhD NIC-ASA Fall Meeting October 15, 2009.

Increasing Survey Cooperation: Motivating Chronic Late Responders to an Annual Survey National Science Foundation Division of Science Resources Statistics.

Joint TC Meeting: EHR – RCRIM RCRIM Overview HL7 Working Group Meeting January, 2007 Presented by: Ed Tripp Program Director, eSubmissions Abbott (RCRIM.

2004 ISHLT J Heart Lung Transplant 2004; 23: HEART TRANSPLANTATION Pediatric Recipients.

Presenter Name(s) Issue date National Student.

Using Cancer Registry Data for Comprehensive Cancer Control Christie Eheman, PhD, National Program of Cancer Registries, Division of Cancer Prevention.

SPRING CREEK ELEMENTARY Title I For additional information contact the school at

10/20/ The Pharmaceutical Industry and Their Influence on Pain Management in the ED J. David Haddox, DDS, MD VP, Risk Management & Health Policy.

Hannover, 14th November 2008 UEVP GA Hungarian Veterinary Chamber From establishment…. to an active European professional body.

Managing Data for Cardiac Outcomes Reporting

County-level Estimates of Diagnosed Diabetes Incidence among Adults aged ≥ 20 years old Trends

Using.NET Platform Note: Most of the material of these slides have been adapted from Nakov’s excellent overview for.NET framework, MSDN and Wikipedia Muhammad.

ACRIN RA Education Sessions Let’s Celebrate 10 years.

AP CALCULUS AB 2012 Question 6 Form A Name_________________ Date __________Period___.

Clinical Epidemiology Study Who benefits? How do we know? B Lynn Beattie MD FRCPC Professor Emeritus Div Geri Med, Dept Med, UBC Medical Director UBCH.

TAKE Solutions Enabling Business Efficiencies Ram Yeleswarapu President & CEO Analysts Meet Mumbai September 18, 2008.

COMPUTER B Y : L K. WINDOWS INFORMATION B Y : L K.

Source: Financial Times of London Global Banks 1999 – 2009 “Changing of the Guard”

Clinical Trials What Are They and When Are They Right For You? Maura N. Dickler Assistant Attending Physician Breast Cancer Medicine Service Memorial Sloan-Kettering.

Rotary Club of Space Center August 6, 1964 – August 6, 2014 Presidents and District Governors.

Drinking Among Junior and Senior High School Students Percent Who Have Consumed Any Alcohol In The Past Month Source: PRIDE Surveys,

CHANGING WORLDS The Impact of University Research.

Name ____________________ Date ___________ Period ____.

Name ____________________ Date ___________ Period ____.

Working in and career progression within an academic clinical trials unit Helen Thorpe Principal Statistician Clinical Trials Research Unit (CTRU) University.

Edward P. Sloan, MD, MPH, FACEP Research Lecture : Basic Statistics.

Basic Statistics: The Three Things You Need to Know In Order to Complete Your Project.

Paula M. Jacobs, Ph.D. SAIC Frederick Cancer Imaging Program/DCTD/NCI/NIH September 5, 2006 Phase 0 Trials in Oncologic Drug Development DCTD Phase 0 Workshop.

Center for Clinical Research - Clinical Trials Center (CTC) Clinical Research and Clinical Trials in Switzerland Jürg Lustenberger, PhD Dipl. Pharm. Med.

County-level Estimates of Diagnosed Diabetes among Adults aged ≥ 20 years: United States 2004

NDA TLC D-99 Doxorubicin HCL Liposome The Liposome Company, Inc. Proposed Indication: “First line treatment of metastatic breast cancer in combination.

1 NCORP Overview November 2013 NCORP Director Worta McCaskill-Stevens, MD, MS Chief, Community Oncology and Prevention Trials Research Group Division of.

Role of the Statistician and the Bioinformatics Scientist in Cancer Clinical Trials Larry Rubinstein, PhD Biometric Research Branch, NCI International.

Yao 1 Neuroendocrine Tumors James C. Yao, MD Associate Professor Deputy Chairman, Gastrointestinal Medical Oncology University of Texas M. D. Anderson.

TAXOL® (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer Oncologic Drugs Advisory Committee September 17, 1999.

ONTAK ® (denileukin diftitox) Post-approval Clinical Commitment Oncologic Drugs Advisory Committee Meeting March 12-13, 2003 Bethesda, MD.

NDA Study MP-US-M01. Division of Oncology Drug Products 2 Federal Food, Drug, and Cosmetic Act of 1962 Substantial Evidence = Adequate and well-controlled.

Overview of All SEER-Medicare Publications Through 2012 Mark D. Danese, MHS, PhD July 24, 2012.

1 Oncologic Drugs Advisory Committee on MTP for Osteosarcoma IDM Pharma, Inc. May 9, 2007 Silver Spring, MD IDM Pharma, Inc. May 9, 2007 Silver Spring,

ODAC SCHERING-PLOUGH RESEARCH INSTITUTE 1 Temozolomide Oncology Drug Advisory Committee March 13, 2003 Craig L. Tendler, M.D. Vice President, Oncology.

Effective Presentation of Study Results How are RCTs presented in abstracts & publications? and Some things to consider in your own presentations NCIC.

Pediatric Study Plans A High Level View

Prostate Cancer: Just The Facts A Mandate for Patient Centered Research Wednesday, June 16, :00 noon – 1:30 pm Rayburn House Office Building Room.

1 orBec ® (oral beclomethasone dipropionate) NDA orBec ® (oral beclomethasone dipropionate) NDA DOR BioPharma, Inc. Oncologic Drugs Advisory.

CI-1 Certican ® (everolimus) Cardiovascular and Renal Drugs Advisory Committee Meeting November 16, 2005.

CI-1 CRESTOR ® (rosuvastatin calcium) Tablets Endocrinologic and Metabolic Drugs Advisory Committee Bethesda, Maryland July 9, 2003 C.

CI-1 Tarceva ® (erlotinib) Tablets in Combination with Gemcitabine as a 1st-line Treatment of Pancreatic Cancer Presentation to the Oncologic Drugs Advisory.

C-IN- 1 Raptiva ™ (efalizumab) Introduction Michelle Rohrer, PhD Director Regulatory Affairs Genentech, Inc.

Initiating phase 1 clinical trials in pediatric oncology National Cancer Institute Perspective Barry Anderson, MD, PhD Pediatric Section Cancer Therapy.

CI-1 ATACAND ® (candesartan cilexetil) Cardiovascular and Renal Drugs Advisory Committee Rockville, Maryland February 24, 2005 C.

A 1 Closing Remarks C. Elaine Jones, Ph.D Vice President Respiratory Regulatory Affairs.

Exjade® (deferasirox; ICL670) NDA

TAXOL® (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer Oncologic Drugs Advisory Committee TAXOL® (paclitaxel) for Adjuvant Treatment.

The President’s Cancer Panel 2004/2005 Series Translating Research to Reduce the Burden of Cancer Margaret L. Kripke, Ph.D. January 25, 2005.

CI-1 Lenalidomide Myelodysplastic Syndromes (Revlimid ®, CC-5013, CDC-501) Graham Burton, MD Senior Vice President Regulatory Affairs Celgene Corporation.

Regulatory Considerations for Endpoints Ann T. Farrell, M.D. FDA/CDER/DODP.

1 Osteosarcoma: The addition of muramyl tripeptide to chemotherapy improves overall survival: A report from the Children’s Oncology Group Paul A. Meyers,

Marital Status and Stage at Diagnosis of Invasive Melanoma of the Skin James (Jay) L. Fisher, Ph.D. Comprehensive Cancer Center and James Cancer Hospital.

Jun Li, MD MPH Epidemic Intelligence Service Officer

Evaluating Quality in Clinical Cancer Research: The M. D

Annual Business Meeting & Class of 2017 Fellows

Clinical Trials in STS Shreyaskumar Patel, M.D.

PhUSE Computational Science

Doctors Hospital Department of Research and Education (DORE)

Figure 1 Osteosarcoma epidemiology

Epidemiology of Myelodysplastic Syndromes

Lessons Learned from the Mistakes of Others

Phase II Trial of Paclitaxel and Cisplatin in Patients with Extensive Stage Small Cell Lung Cancer: Cancer and Leukemia Group B Trial 9430 Thomas E.

Presentation transcript:

1 Oncologic Drugs Advisory Committee on MTP for Osteosarcoma IDM Pharma, Inc. May 9, 2007 Silver Spring, MD IDM Pharma, Inc. May 9, 2007 Silver Spring, MD

2 Bonnie Mills, PhD Vice President, Clinical Operations IDM Pharma Vice President, Clinical Operations IDM Pharma

3 MTP Sponsors Ciba-Geigy Non-clinical and Phase 1/2 studies NCI Cooperative Group Phase 3 trial Jenner Biotherapies IDM 2003-present Completed Phase 3 primary final analysis2004 Submitted NDA

4 Phase 3 Trial Large, well conducted, multi-center study in osteosarcoma (NCI/COG) Clinically meaningful effect –DFS (primary):p = , HR = 0.76, 95% CI (0.58, 0.98) –Survival: p = , HR = 0.68, 95% CI (0.49, 0.95) Subset analyses support internal consistency Confirmatory study “practically or ethically impossible”

5 AgendaAgenda Unmet NeedIan Lewis, MB ChB, FRCP, FRCPCH Paediatric and Adolescent Oncologist St James University Hospital, Leeds Product Characteristics Bonnie Mills, PhD IDM Pharma Efficacy/SafetyPaul Meyers, MD Vice-Chairman, Dept of Pediatrics Memorial Sloan-Kettering Cancer Center Statistical Interpretation Brent Blumenstein, PhD Trial Architecture Consulting Benefit/RiskEugenie Kleinerman, MD Professor and Head, Division of Pediatrics MD Anderson Cancer Center

6 Resources and References Clinical –Curt Scribner, MD –Cheryl Graham, MD Statistics –Mark Munsell –Neby Bekele, PhD Nonclinical –Olivier Faure, PhD Regulatory –Tung Koh COG Statistician –Mark Krailo, PhD Software Citation: Surveillance Research Program, National Cancer Institute SEER*Stat software ( version Data Citation: Surveillance, Epidemiology, and End Results (SEER) Program ( SEER*Stat Database: Incidence - SEER 9 Regs Limited-Use, Nov 2004 Sub ( ), National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2005, based on the November 2004 submission.